Three groundbreaking studies presented this week at the American Society of Clinical Oncology’s annual meeting in Chicago are reshaping the conversation around GLP-1 medications—drugs like Ozempic and Wegovy—from weight-loss tools to potential cancer-prevention powerhouses. The data, drawn from over 110,000 patients, suggests these drugs could cut breast cancer risk by up to 30%, reduce metastasis by half, and lower mortality rates by 6%. But experts warn: the findings are observational, not definitive proof. What we do know is that the science is moving faster than the regulatory process—and the implications could be life-changing.
A 30% Drop in Breast Cancer Risk: The Numbers That Stopped Oncologists in Their Tracks
The most striking figure comes from a retrospective analysis of 110,000 women aged 45 to 80 with a BMI of 25 or higher—the “overweight” threshold. Nearly 14% of them had prescriptions for GLP-1 medications, and the results were dramatic: those who took the drugs were 30.5% less likely to develop breast cancer, even after accounting for age, race, ethnicity, BMI, breast density, and diabetes status. The study, presented by Dr. Elizabeth McDonald of the University of Pennsylvania and Abramson Cancer Center, didn’t track how long participants used the drugs, but the correlation was undeniable.
What’s more, a second study found that adding GLP-1 medications to standard breast cancer treatment reduced the risk of death from the disease by 30%. A third study, encompassing breast, lung, bowel, and liver cancers, showed that patients on these drugs were up to 50% less likely to see their cancer spread. The data was shared at ASCO’s annual meeting, where oncologists described the findings as “the most compelling evidence yet” linking weight-loss drugs to cancer outcomes.
“Our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, but it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools.”
—Dr.
McDonald’s caution is well-placed. Observational studies can’t prove causation, but they do raise urgent questions. If GLP-1s are indeed reducing cancer risk, how? The leading theories focus on inflammation, metabolism, and epigenetic effects. Obesity is a known risk factor for breast cancer—especially post-menopause—and GLP-1 drugs are highly effective at promoting weight loss. But the drugs also reduce systemic inflammation, a process linked to tumor growth, and may influence pathways tied to cancer development. McDonald’s team is now launching a clinical trial to test whether these drugs can lower breast cancer incidence in high-risk women—a critical next step.
Beyond Breast Cancer: The Broader Implications for Oncology
The ASCO presentations didn’t stop at breast cancer. Researchers also highlighted reduced risks for lung, bowel, and liver cancers—though the data was less robust. What’s clear is that GLP-1 medications are affecting multiple pathways tied to cancer progression. These drugs weren’t designed for oncology; they were originally developed for type 2 diabetes and later repurposed for weight management. Yet their off-label effects—on inflammation, insulin resistance, and even gut microbiome health—are now under intense scrutiny.
One theory gaining traction is that GLP-1s may influence the tumor microenvironment, the cellular ecosystem that surrounds and feeds cancers. Early research suggests these drugs could suppress angiogenesis (the formation of new blood vessels that tumors rely on) and modulate immune responses. If confirmed, it would mark one of the most serendipitous drug repurposings in modern medicine—turning a weight-loss tool into a potential cancer preventive.
The Catch: Why Oncologists Aren’t Yet Prescribing GLP-1s for Cancer Prevention
Here’s the hard truth: these studies are observational, not randomized controlled trials. Correlation isn’t causation. And while the numbers are compelling, they don’t yet justify doctors prescribing GLP-1s to patients solely for cancer prevention. The FDA hasn’t approved these drugs for oncology, and insurers may not cover them off-label. Yet the momentum is undeniable.
Dr. McDonald’s team is already designing a clinical trial to test whether GLP-1s can prevent breast cancer in high-risk women—a process that could take years. Meanwhile, pharmaceutical companies are watching closely. Eli Lilly, the maker of Zepbound (a GLP-1 drug), has already signaled interest in exploring oncology applications. But regulatory hurdles remain. The FDA’s Oncology Center of Excellence would need to review new data before any drug could be repurposed, a process that typically takes 2–5 years.
There’s also the practical question: who would get access? GLP-1 drugs are expensive—Wegovy costs around $1,300 per month without insurance—and their side effects (nausea, diarrhea, rare but serious risks like pancreatitis) aren’t trivial. If these drugs are proven to prevent cancer, would they become a luxury for the wealthy, or would payers expand coverage? The ethical dilemmas are just beginning to surface.
What Comes Next: The Timeline for Answers
The next 12–24 months will be critical.
- Clinical trials: McDonald’s team is recruiting for a prevention study in high-risk women. Results could emerge as early as 2028.
- Regulatory interest: The FDA may accelerate reviews if more observational data emerges. Look for guidance updates by late 2027.
- Pharma investments: Companies like Eli Lilly and Novo Nordisk (maker of Ozempic) are likely to fund oncology research. Expect announcements in the next 6–12 months.
- Real-world data: As more patients use GLP-1s for weight loss, electronic health records will provide larger datasets to study cancer outcomes.
The bigger question is whether GLP-1s will become a first-line preventive tool—or just one piece of a broader strategy. Even if these drugs cut cancer risk by 30%, they won’t eliminate it. The real breakthrough may lie in combining them with other interventions: lifestyle changes, targeted screenings, and emerging therapies like immunotherapy.
“Ultimately, we want to find better options to prevent breast cancer. It’s been encouraging to see the survival rates improve over recent decades, and we’d love to see the same gains in prevention.”
—Dr.
For now, the message to patients is clear: these findings are promising but not yet actionable. If you’re considering GLP-1 drugs for weight loss, discuss them with your doctor—but don’t expect a cancer prevention prescription anytime soon. The science is moving fast, but medicine moves slower. What’s certain is that the conversation has changed forever.
For readers exploring this topic further, the Guardian’s coverage of the ASCO presentations provides additional context on the study designs, while ScienceAlert’s breakdown highlights the broader implications for oncology research.
